Form 990 for tax year 2024
Filed by FRIEDREICHS ATAXIA RESEARCH ALLIANCE FARA.
Totals
- Total revenue
- $13,135,426
- Total expenses
- $13,277,236
- Contributions and grants received
- $13,517,065
- Grants paid
- $10,467,810
- Program service revenue
- $0
- Investment income
- $172,331
- Other revenue
- -$553,970
- Total assets, end of year
- $6,946,549
- Total liabilities, end of year
- $676,182
- Net assets or fund balances, end of year
- $6,270,367
- Program services expenses (Part IX)
- $12,534,019
- Management and general expenses
- $374,757
- Fundraising expenses
- $368,460
- Program service expenses (Part III)
- $12,534,019
Program services were 94.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1a · Federated campaigns
$7,072
-
1c · Fundraising events
$3,362,180
-
1f · All other contributions, gifts and grants
$10,147,813
-
1g · Noncash contributions included above
$881,511
-
3 · Investment income
total $145,621 · excluded $145,621
-
7a · Gross sales of assets other than inventory
securities $645,455
-
7b · Less cost or other basis and sales expenses
securities $618,745
-
7c · Gain or loss
securities $26,710
-
7d · Net gain or loss
total $26,710 · excluded $26,710
-
8a · Fundraising events: gross income
$648,785
-
8a · Fundraising events: contributions included on line 1c
$3,362,180
-
8b · Fundraising events: direct expenses
$1,202,755
-
8c · Net income from fundraising events
total -$553,970 · excluded -$553,970
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $7,117,301 · program services $7,117,301
-
2 · Grants to domestic individuals
total $13,350 · program services $13,350
-
3 · Grants to foreign organizations and individuals
total $3,337,159 · program services $3,337,159
-
5 · Compensation of officers, directors and key employees
total $352,453 · program services $235,494 · management and general $77,129 · fundraising $39,830
-
7 · Other salaries and wages
total $1,005,136 · program services $743,605 · management and general $145,566 · fundraising $115,965
-
8 · Pension plan contributions
total $22,699 · program services $17,493 · management and general $3,331 · fundraising $1,875
-
9 · Other employee benefits
total $94,846 · program services $79,156 · management and general $5,460 · fundraising $10,230
-
10 · Payroll taxes
total $97,523 · program services $72,766 · management and general $15,658 · fundraising $9,099
-
11c · Fees: accounting
total $28,777 · management and general $28,777
-
11d · Fees: lobbying
total $7,550 · program services $7,550
-
11g · Fees: other
total $487,223 · program services $383,230 · management and general $10,373 · fundraising $93,620
-
13 · Office expenses
total $16,786 · program services $1,995 · management and general $5,023 · fundraising $9,768
-
16 · Occupancy
total $47,789 · program services $32,849 · management and general $8,264 · fundraising $6,676
-
19 · Conferences, conventions and meetings
total $250,194 · program services $198,384 · management and general $47,520 · fundraising $4,290
-
23 · Insurance
total $15,021 · program services $2,486 · management and general $9,213 · fundraising $3,322
-
24a · Other expenses: SUBSCRIPTIONS & LICENSI
total $306,389 · program services $280,541 · management and general $0 · fundraising $25,848
-
24b · Other expenses: CREDIT CARD & BANK FEES
total $27,790 · program services $213 · management and general $397 · fundraising $27,180
-
24c · Other expenses: FACILITIES & EQUIPMENT
total $15,239 · program services $1,000 · management and general $14,239 · fundraising $0
-
24d · Other expenses: PRINTING AND COPYING
total $13,354 · program services $4,091 · management and general $1,125 · fundraising $8,138
-
24e · All other expenses
total $20,657 · program services $5,356 · management and general $2,682 · fundraising $12,619
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $3,076,159 · end of year $1,776,063
-
2 · Savings and temporary cash investments
beginning of year $1,880,952 · end of year $2,220,120
-
3 · Pledges and grants receivable
beginning of year $766,590 · end of year $693,221
-
9 · Prepaid expenses and deferred charges
beginning of year $49,155 · end of year $67,503
-
11 · Investments: publicly traded securities
beginning of year $1,870,166 · end of year $1,705,100
-
12 · Investments: other securities
end of year $432,680
-
13 · Investments: program-related
beginning of year $5,458 · end of year $5,458
-
15 · Other assets
beginning of year $103,796 · end of year $46,404
-
17 · Accounts payable and accrued expenses
beginning of year $1,489,034 · end of year $615,612
-
19 · Deferred revenue
beginning of year $4,567 · end of year $10,630
-
25 · Other liabilities
beginning of year $112,047 · end of year $49,940
-
27 · Net assets without donor restrictions
beginning of year $5,182,849 · end of year $3,919,967
-
28 · Net assets with donor restrictions
beginning of year $963,779 · end of year $2,350,400
Mission and programs · 2024
Mission
TO MARSHAL AND FOCUS THE RESOURCES AND RELATIONSHIPS NEEDED TO CURE FA BY RAISING FUNDS FOR RESEARCH, PROMOTING PUBLIC AWARENESS AND ALIGNING SCIENTISTS, PATIENTS, CLINICIANS, GOVERNMENT AGENCIES AND PHARMACEUTICAL COMPANIES DEDICATED TO CURING FA AND RELATED DISORDERS.
Activities or mission (Part I)
TO TREAT AND CURE FRIEDREICH'S ATAXIA (FA) BY ADVANCING RESEARCH, AWARENESS AND PARTNERSHIPS.
-
RESEARCH AND GRANT PROGRAM - SEE SCHEDULE O
Expenses $10,330,478 · Grants $9,606,747
-
CLINICAL RESEARCH INFRASTRUCTUREIN ADDITION TO RESEARCH GRANTS, FARA FUNDS THE ONGOING DEVELOPMENT OF DOMAIN RESOURCES IN THE FORM OF VITAL CLINICAL RESEARCH INFRASTRUCTURE. CLINICAL RESEARCH INFRASTRUCTURE REFERS TO THE RESOURCES NEEDED TO FACILITATE ANY TYPE OF RESEARCH, INCLUDING CLINICAL TRIALS THAT INVOLVE PATIENTS. THESE RESOURCES INCLUDE PROGRAMS LIKE: FRIEDREICH'S ATAXIA GLOBAL PATIENT REGISTRY: THE FRIEDREICH'S ATAXIA GLOBAL PATIENT REGISTRY (FAGPR) IS THE ONLY WORLDWIDE REGISTRY OF FRIEDREICH'S ATAXIA PATIENTS. THE GOALS OF THE FAGPR ARE TO COLLECT INFORMATION ON ALL FA PATIENTS IN ONE REGISTRY, TO DEVELOP THE REGISTRY INTO A POWERFUL RESOURCE FOR RESEARCH, AND TO ENGAGE THE FA COMMUNITY IN STUDIES AIMED AT ADVANCING OUR KNOWLEDGE (CONTINUED IN SCHEDULE O)CLINICAL RESEARCH INFRASTRUCTURE (CONT'D):OF FA AND THE TREATMENTS BEING DEVELOPED. FARA PARTNERS WITH INTERNATIONAL PATIENT ADVOCACY ORGANIZATIONS THROUGH A GOVERNANCE BOARD TO ENSURE MULTI-STAKEHOLDER ENGAGEMENT AND OVERSIGHT OF THE FAGPR. MORE THAN 1000 INDIVIDUALS WITH FA ARE ENROLLED AND FAGPR WAS USED TO RECRUIT FOR SEVERAL CLINICAL TRIALS AND MANY CLINICAL RESEARCH STUDIES. TO LEARN MORE, VISIT CUREFA.NET/REGISTRY. FA GLOBAL CLINICAL CONSORTIUM: FARA AND THE FA COMMUNITY'S DEDICATION TO COLLECTING NATURAL HISTORY STUDY DATA OVER THE PAST TWO DECADES PROVED INSTRUMENTAL IN THE APPROVAL OF THE FIRST-EVER TREATMENT FOR FA. THROUGH THE FA GLOBAL CLINICAL CONSORTIUM (FA GCC), FARA HAS REDOUBLED ITS INVESTMENT IN NATURAL HISTORY DATA BY ENABLING THE TRANSITION TO AN INDUSTRY-LEADING DATA COLLECTION PLATFORM AND A UNIFIED GLOBAL NATURAL HISTORY PROTOCOL (UNIFAI) RESULTING FROM THE HARMONIZATION OF TWO WELL-ESTABLISHED NATURAL HISTORY STUDIES, THE FA CLINICAL OUTCOME MEASURES STUDY (FA-COMS) AND THE EUROPEAN FRIEDREICH'S ATAXIA CONSORTIUM FOR TRANSLATIONAL STUDIES (EFACTS). THE FA GCC AND THE UNIFAI STUDY HAVE BEEN EXPANDED TO MAKE PATIENT CONTRIBUTIONS TO NATURAL HISTORY EVEN MORE POWERFUL IN UNDERSTANDING FA, EVALUATING THE IMPACT OF TREATMENT OPTIONS FOR FA, ACCELERATING THE DEVELOPMENT OF NEW THERAPIES AND IMPROVING OUTCOMES FOR THOSE LIVING WITH FA. AT EACH UNIFAI STUDY VISIT THERE ARE MORE THAN 1400 DATA ELEMENTS RECORDED. OVER THE LAST TWO YEARS, THE FA GCC HAD ACTIVE PARTICIPATION FROM 54 INVESTIGATORS FROM 33 SITES REPRESENTING 18 COUNTRIES ALONG WITH REPRESENTATIVES FROM PATIENT ADVOCACY AND RESEARCH ORGANIZATIONS. FA GCC RESEARCH ACTIVITIES: THE FA GCC LEADERSHIP IDENTIFIED INITIAL SCIENTIFIC PRIORITIES AND CREATED WORKGROUPS TO ADDRESS THESE PRIORITIES. THE FOLLOWING WORK GROUPS, EACH MADE UP OF 5-10 CONSORTIUM MEMBERS, MET REGULARLY TO ADDRESS GAPS IN CURRENT FA RESEARCH: CARDIAC NATURAL HISTORY, LATE-STAGE SYMPTOMS, PEDIATRIC / PRESYMPTOMATIC, BIO-SAMPLES, MOOD AND COGNITION, AND PATIENT ADVOCACY/ADVISORY TEAM. QUARTERLY FULL GROUP MEETINGS SERVE AS A PLATFORM FOR INVESTIGATORS TO ESTABLISH COMMON RESEARCH INTERESTS, FORM COLLABORATIONS, AND SHARE THEIR GLOBAL EXPERIENCES WITH OMAVELOXOLONE. IMPACT AND FUTURE DIRECTION: THE CONSORTIUM HAS A LONG-TERM OBJECTIVE OF FOSTERING MULTILATERAL RESEARCH AND COLLABORATION ACROSS CONTINENTS, UNIFYING GLOBAL OPINIONS TO REGULATORS AND INDUSTRY PARTNERS, ACCELERATING THE DEVELOPMENT OF NEW THERAPIES, AND IMPROVING OUTCOMES FOR THOSE LIVING WITH FA. ADDITIONAL INFORMATION ABOUT FARA'S PROGRAMS IN 2024 CAN BE ACCESSED VIA THE ANNUAL REPORT AT: CUREFA.ORG
Expenses $1,354,745 · Grants $781,063
-
AWARENESS, EDUCATION, AND OUTREACH PROGRAMS:AWARENESS: FRIEDREICH ATAXIA (FA) IS A RARE DISEASE; AFFECTING 1 IN 50,000 INDIVIDUALS. FARA IS DEDICATED TO ADVOCACY AND RAISING AWARENESS FOR FA. FARA HAS UTILIZED BOTH TRADITIONAL AND SOCIAL MEDIA STRATEGIES TO BRING GREATER AWARENESS TO FA IN THE GENERAL PUBLIC AND TO ENGAGE AND EDUCATE THE FA COMMUNITY. FOR EXAMPLE, FARA CONDUCTS AN ANNUAL A SOCIAL MEDIA CAMPAIGN THAT ENCOURAGES COMMUNITY PARTICIPATION LEADING UP TO FA AWARENESS DAY. ADVOCACY: FARA AND THE NATIONAL ATAXIA FOUNDATION (NAF) PARTNERED ON SEVERAL ADVOCACY INITIATIVES RELEVANT TO THE ATAXIA COMMUNITY. MOSTLY NOTABLY, THE EFFORTS OF THE TWO ORGANIZATIONS RESULTED IN THE CONTINUED INCLUSION OF HEREDITARY ATAXIA AS PART OF (CONTINUED IN SCHEDULE O)ADVOCACY: (CONT'D)THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM (CDMRP) AT THE DEPARTMENT OF DEFENSE IN FISCAL YEAR (FY) 24, RESULTING IN FOUR HEREDITARY ATAXIA RESEARCH GRANTS BEING RECOMMENDED FOR FUNDING TOTALING OVER $12 MILLION. FARA AND NAF WERE ALSO SUCCESSFUL IN GETTING A RESOLUTION PASSED DECLARING SEPTEMBER 25, 2024 NATIONAL ATAXIA AWARENESS DAY AND HOSTING THE SIXTH UNITED AGAINST ATAXIA HILL DAY- WITH 94 CONGRESSIONAL MEETINGS FEATURING THE PARTICIPATION OF 113 FARA AND NAF ADVOCATES FROM 32 STATES. EDUCATION: IN AN ONGOING EFFORT TO SHARE INFORMATION AND EDUCATION, FARA LAUNCHED A NEW WEBSITE IN 2024. THE SITE REDESIGN PRIORITIZED THE USER EXPERIENCE FOR KEY STAKEHOLDERS INCLUDING PATIENT FAMILIES, RESEARCHERS, AND DONORS. THE NEW SITE COINTAINS UP-TO-DATE INFORMATION ON FA RESEARCH INCLUDING GRANTS FUNDED BY FARA, TREATMENT APPROACHES AND PROGRAMS IN THE DRUG DEVELOPMENT PIPELINE, RESEARCH RESOURCES, AND CLINICAL TRIAL OPPORTUNITIES. IT ALSO OFFERS GUIDANCE FOR FAMILIES NAVIGATING FA AND OPPORTUNITIES TO CONNECT WITH OTHERS AND GET INVOLVED.ENGAGING WITH STAKEHOLDERS: AS EXPERTS IN LIVING WITH FA, INDIVIDUALS AND FAMILIES SHARED THEIR STORIES IN MANY FORUMS AND TO MANY AUDIENCES. IN 2024, OVER 50 INDIVIDUALS FROM THE FA COMMUNITY WORKED WITH FARA TO ENGAGE WITH PHARMACEUTICAL PARTNERS, RESEARCHERS, FUTURE HEALTHCARE PROFESSIONALS, MEDICAID COMMITTEES, AND THE FOOD AND DRUG ADMINISTRATION AT 33 DIFFERENT EVENTS. THEIR VOICES PROVIDE ESSENTIAL INSIGHTS THAT ADVANCE MEANINGFUL AND ACCESSIBLE TREATMENTS. CULTIVATING COMMUNITY: THROUGHOUT 2024, FARA WORKED TO STRENGTHEN THE FA COMMUNITY BY FACILITATING OPPORTUNITIES FOR CONNECTION AND COLLABORATION THROUGH VIRTUAL AND IN-PERSON EVENTS. INDIVIDUALS NEW TO THE FA COMMUNITY HAD THE OPPORTUNITY TO MEET OTHER FA FAMILIES FOR THE FIRST TIME. THE FARA AMBASSADOR PROGRAM, A GROUP OF ADULTS WITH FA WHO VOLUNTEER TO SUPPORT FARA'S MISSION, GREW TO 100 MEMBERS FROM COUNTRIES AROUND THE WORLD. AMBASSADORS NOW REPRESENT 14 COUNTRIES GLOBALLY PLUS 32 STATES THROUGHOUT THE US.TO HELP FURTHER FARA'S AWARENESS AND OUTREACH INITIATIVES, FARA ALSO FUNDED A GRANT FOR THE CREATION OF A DOCUMENTARY FILM ABOUT HOW THE FA COMMUNITY UNITES TO ADVANCE RESEARCH. THE FILM, UNDER THE WORKING TILE "THE HIGHEST ROAD," FOCUSES ON THE FA COMMUNITY'S ROLE IN HELPING TO GET THE FIRST DRUG APPROVED FOR FA A STORY THAT IS TOLD IN PARALLEL WITH COMMUNITY MEMBERS ATTEMPTING TO CYCLE UP THE HIGHEST PAVED ROAD IN INDIA. THE FILM IS CURRENTLY IS POST PRODUCTION WITH THE AIM TO BE SHOWN IN FILM FESTIVALS IN 2026.
Expenses $491,179 · Grants $80,000
-
WORKSHOPS, SYMPOSIA, & CONFERENCESINTERNATIONAL CONGRESS FOR ATAXIA RESEARCHIN NOVEMBER 2024, THE INTERNATIONAL CONGRESS FOR ATAXIA RESEARCH (ICAR) BROUGHT TOGETHER OVER 600 RESEARCHERS FROM AROUND THE WORLD. IT WAS THE LARGEST ICAR TO DATE AND A POWERFUL EXAMPLE OF HOW WE ACCELERATE PROGRESS WHEN EXPERTS ACROSS DIFFERENT TYPES OF ATAXIA COME TOGETHER TO SHARE IDEAS AND COLLABORATE. FARA WAS HONORED TO CO-HOST THE MEETING ALONG WITH ATAXIA UK, NATIONAL ATAXIA FOUNDATION, AND THE ATAXIA GLOBAL INITIATIVE.THIS YEAR'S PROGRAM INCLUDED A MIX OF PLENARY SESSIONS, BREAKOUT WORKSHOPS, AND SCIENTIFIC DEBATE. THE DEBATE SPARKED THOUGHTFUL DISCUSSION ABOUT THE STRENGTHS OF IN VIVO VS. IN VITRO RESEARCH MODELS AND HIGHLIGHTED HOW BOTH APPROACHES HELP TO MOVE THE SCIENCE FORWARD.SOME INSIGHTS AND LEARNINGS FROM ICAR 2024 INCLUDED: 1. DISCOVERING THAT FRATAXIN ACTIVITY CAN BE BOOSTED BY TARGETING OTHER COMPONENTS OF THE IRON-SULFUR CLUSTER ASSEMBLY REVEALS A POTENTIAL NEW TREATMENT PATHWAY. 2. SOME GAA REPEAT INTERRUPTIONS ARE MORE COMMON THAN PREVIOUSLY KNOWN, IMPACTING CARRIER DETECTION AND OPENING NEW THERAPEUTIC OPPORTUNITIES. 3. INFLAMMATION MIGHT CONTRIBUTE TO NERVE DAMAGE IN FA. 4.CAPSID FOR AN IV GENE ADDITION THERAPY REACHED KEY BRAIN AND HEART AREAS IN ANIMAL MODELS 5. MULTIPLE THERAPIES ACROSS DIFFERENT MECHANISMS OF ACTION ARE SHOWING EARLY PROMISE.FARA ALSO HOSTED FIVE RESEARCH RECEPTIONS AND SYMPOSIUMS TO SHARE INFORMATION ABOUT THE FA DRUG DEVELOPMENT PIPELINE, ONGOING CLINICAL TRIALS, CLINICAL MANAGEMENT, AND FARA RESOURCES. VIRTUAL EDUCATION SESSIONS INCLUDED FLASH TALKS WITH FARA-FUNDED RESEARCHERS, COMMUNITY CONVERSATION WEBINARS WITH FARA LEADERSHIP, AND INFORMATION SESSIONS WITH PHARMACEUTICAL PARTNERS.
Expenses $357,617
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Ronald BartekRONALD BARTEK
PRESIDENT/DIRECTOR
- Total calculated
- $113,811
- From this org
- $110,000
- From related orgs
- $0
- Other
- $3,811
- Hours/week
- 40
-
Ruth ActonRUTH ACTON
TREASURER/DIRECTOR FINANCE
- Total calculated
- $67,964
- From this org
- $51,000
- From related orgs
- $0
- Other
- $16,964
- Hours/week
- 25
-
Paul AveryPAUL AVERY
CHAIRMAN/ DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Maureen JuipMAUREEN JUIP
SECRETARY/ DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr Sanjay BidichandaniDR SANJAY BIDICHANDANI
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Brigid BrennanBRIGID BRENNAN
DIRECTOR/ GENERAL COUNSEL
- Total calculated
- $0
- Hours/week
- 20
-
Thomas BrenninkmeijerTHOMAS BRENNINKMEIJER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Alex FieldingALEX FIELDING
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Jennifer GoodJENNIFER GOOD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Thomas HamiltonTHOMAS HAMILTON
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr Holly HedrickDR HOLLY HEDRICK
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Derek G HenneckeDEREK G HENNECKE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Warren HuffWARREN HUFF
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr Steve KlaskoDR STEVE KLASKO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr Kathy MathewsDR KATHY MATHEWS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr James McArthurDR JAMES MCARTHUR
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Tony PlohorosTONY PLOHOROS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Patrick RitschelPATRICK RITSCHEL
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Dr James R RuscheDR JAMES R RUSCHE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 10
-
Jennifer M FarmerJENNIFER M FARMER
CHIEF EXECUTIVE OFFICER
- Total calculated
- $170,678
- From this org
- $165,000
- From related orgs
- $0
- Other
- $5,678
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $165,000
- Bonus
- $0
- Other
- $0
- Deferred
- $4,950
- Nontaxable benefits
- $728
- Filer's total
- $170,678
-
Barbara A TateBARBARA A TATE
CHIEF SCIENTIFIC OFFICER
- Total calculated
- $255,527
- From this org
- $250,000
- From related orgs
- $0
- Other
- $5,527
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $250,000
- Bonus
- $0
- Other
- $0
- Deferred
- $4,833
- Nontaxable benefits
- $694
- Filer's total
- $255,527
-
Elisabetta SoragniELISABETTA SORAGNI
DIRECTOR OF RESEARCH
- Total calculated
- $131,874
- From this org
- $115,851
- From related orgs
- $0
- Other
- $16,023
- Hours/week
- 40
-
Felicia DerosaFELICIA DEROSA
VP FUNDRAISING & COMMS
- Total calculated
- $118,643
- From this org
- $106,351
- From related orgs
- $0
- Other
- $12,292
- Hours/week
- 40
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
$1,945,086
MEDICAL RESEARCH
-
MEDICAL RESEARCH
-
MEDICAL RESEARCH
-
$359,182
MEDICAL RESEARCH
-
REGENTS OF THE UNIVERSITY OF MINNESOTA
$339,615
MEDICAL RESEARCH
-
MASSACHUSETTS GENERAL HOSPITAL
$313,988
MEDICAL RESEARCH
-
UNIVERSITY OF MASSACHUSETTS
$300,000
MEDICAL RESEARCH
-
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
$274,855
MEDICAL RESEARCH
-
$250,000
MEDICAL RESEARCH
-
VESIGEN INC
$204,136
MEDICAL RESEARCH
The 10 largest by cash amount. The API serves every itemized grant.
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
STICHTING FRIEDREICH'S ATAXIA RESEARCH ALLIANCE EUROPE
RESEARCH · NL
Directly controlled by FRIEDREICH'S ATAXIA RESEARCH ALLIANCE
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 15 October 2025
- IRS schema version
- 2024v5.2
- Source object
- 202542899349301714
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.